2023-02 – Q4 2022 Reporting
New Zealand authorities approved the protocol with dosing of SER150 or placebo for six months. All clinical centers in Australia and New Zealand ready to initiate screening of patients in…
2023-01 – New CEO in Serodus ASA
Serodus ASA’s Board of Directors has in agreement with our CEO Eva Steiness decided to relieve her for the administrative burden to manage Serodus ASA from her permanent address in…
2022-10 – Q3 2022 Reporting
Transition to the new Australian based CRO was finalized during Q3.Australian ethical committee has approved increasing dosing period from 3 to 6 months.Reactivation of Australian centers by the new CRO.Centers…
2022-10 – European Patent office has Published a SER150 patent 19th October 2022
European Patent office has Published a SER150 patent 19th October 2022Download
2022-08 – Q2 2022 Reporting
Still low number of patients entered the study in Q2-2022.A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.Complete transfer expected to be…
2022-07 – Serodus ASA – Minutes of Annual General Meeting 2022
Download: Presentation AGM 2022 Download: Minutes from General Meeting
2022-05 – Serodus ASA – Notice of postponement
AGM 2022 to be postponed until late june 2022 Read more
2022-05 – 2021 Annual Report
SERODUS ASA - Publishes 2021 Annual Report Download it here
2022-05 – Q1 2022 Reporting
Highlights SER150 clinical study in Australia is still delayed after Covid19 lockdownsSerodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.The Group qualified for and received a “Patent…